The U.S. FDA has approved UroGen Pharma's (NASDAQ:URGN) recurrent low-grade intermediate-risk non-muscle invasive bladder cancer drug Zusduri (mitomycin).
Approval was based on the results of a single-arm trial in which patients received mitomycin once a week for six weeks. Efficacy was
